Takeda Pharmaceutical (NYSE:TAK) Hits New 1-Year High – What’s Next?

Takeda Pharmaceutical Co. (NYSE:TAK)’s stock price hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $16.48 and last traded at $16.4050, with a volume of 683043 shares changing hands. The stock had previously closed at $16.01.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Morgan Stanley initiated coverage on Takeda Pharmaceutical in a research note on Tuesday. They set an “overweight” rating for the company. Weiss Ratings reiterated a “hold (c-)” rating on shares of Takeda Pharmaceutical in a report on Monday, December 29th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold”.

Takeda Pharmaceutical Price Performance

The stock has a 50-day moving average price of $14.88 and a two-hundred day moving average price of $14.71. The company has a current ratio of 1.37, a quick ratio of 0.76 and a debt-to-equity ratio of 0.61. The stock has a market cap of $51.39 billion, a price-to-earnings ratio of 10.60 and a beta of 0.03.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings results on Thursday, October 30th. The company reported $0.44 EPS for the quarter, meeting analysts’ consensus estimates of $0.44. The company had revenue of $7.30 billion during the quarter, compared to analysts’ expectations of $8.01 billion. Takeda Pharmaceutical had a return on equity of 10.32% and a net margin of 0.86%.Takeda Pharmaceutical has set its FY 2025 guidance at 3.250-3.250 EPS. As a group, equities research analysts forecast that Takeda Pharmaceutical Co. will post 1.64 EPS for the current year.

Institutional Trading of Takeda Pharmaceutical

Several large investors have recently bought and sold shares of TAK. Capital Research Global Investors increased its stake in Takeda Pharmaceutical by 0.8% during the 3rd quarter. Capital Research Global Investors now owns 13,404,129 shares of the company’s stock valued at $196,236,000 after purchasing an additional 108,556 shares in the last quarter. UBS Group AG grew its holdings in shares of Takeda Pharmaceutical by 46.4% during the third quarter. UBS Group AG now owns 5,893,969 shares of the company’s stock valued at $86,288,000 after buying an additional 1,869,323 shares during the last quarter. Goldman Sachs Group Inc. increased its position in shares of Takeda Pharmaceutical by 15.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company’s stock valued at $79,120,000 after acquiring an additional 692,404 shares during the period. Brandes Investment Partners LP increased its position in shares of Takeda Pharmaceutical by 5.9% in the 2nd quarter. Brandes Investment Partners LP now owns 3,712,278 shares of the company’s stock valued at $57,392,000 after acquiring an additional 208,136 shares during the period. Finally, Arrowstreet Capital Limited Partnership raised its stake in Takeda Pharmaceutical by 132.1% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,828,778 shares of the company’s stock worth $41,413,000 after acquiring an additional 1,610,088 shares during the last quarter. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.